Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a ...

Explore the rise and market race of anti-IL23p19 therapies in Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC). Stay informed on the latest advancements and treatment options.